Thomas Pulliam

8PUBLICATIONS
62CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGenomics and transcriptomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 04, 2026
Response of B Cells Specific for Polyomavirus-Derived Oncoprotein Is Predictive of Merkel Cell Carcinoma Tumor Control.

Haroldo J Rodriguez Chevez, Allison J Remington, Matthew D Gray

|Oct 23, 2025
Circulating Neoantigen- and Viral Oncoprotein-Specific CD8+ T Cells Share a Transcriptional Signature.

Saumya Jani, Tomas Bencomo, Carolyn Shasha

|Aug 11, 2025
Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade.

Lisa Tachiki, Yasman Moshiri, Daniel S Hippe

|Oct 14, 2024
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses.

Thomas Pulliam, Saumya Jani, Peter H Goff

|Oct 18, 2023
Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade.

Shira Tabachnick-Cherny, Thomas Pulliam, Haroldo J Rodriguez

|Oct 17, 2022
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.

Candice Church, Thomas Pulliam, Natalie Longino

Pageof 2

Frequent Collaborators

8 joint publications

Paul T Nghiem

5 joint publications

Candice D Church

5 joint publications

David M Koelle

5 joint publications

Kimberly Smythe